Paxlovid—Pfizer’s antiviral Covid-19 treatment—is 37% effective at preventing hospitalization or death in high-risk patients compared with no treatment, according to a study published Thursday in the JAMA Network Open, well below the 88% effectiveness rate Pfizer and regulators reported in clinical trials in 2021—though it remains very effective at staving off death.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,